ATL shifts sales focus to high-end ultrasound

Article

Sales of ATL's high-end Ultramark 9 scanner into the radiologyultrasound market boosted that company's revenue over the pasttwo years. But this positive trend was diminished by a declinein revenue from lower end scanners. The Bothell, WA, vendor ismoving

Sales of ATL's high-end Ultramark 9 scanner into the radiologyultrasound market boosted that company's revenue over the pasttwo years. But this positive trend was diminished by a declinein revenue from lower end scanners. The Bothell, WA, vendor ismoving away from that sector of the market.

ATL will become an independent ultrasound company this monthas its sister company, patient monitor supplier SpaceLabs, spinsoff into a separate publicly held company. That split was approvedby shareholders of parent holding company Westmark Internationalin May.

Going it alone, ATL now must reveal its sales and income figuresto shareholders, as do competitor Acuson and other publicly helddedicated ultrasound vendors.

ATL and SpaceLabs were originally medical equipment units ofSquibb and were spun off from that pharmaceutical company in 1986under the Westmark umbrella. SpaceLabs has had slightly less revenueand considerably more profit than ATL in the subsequent years,according to the Westmark proxy statement provided to shareholdersfor the vote last month.

ATL's revenues actually declined 2.6% in fiscal 1991 (end-December),from $287 million in 1990 to $280 million. Net income, however,rose 9% last year, from $6.6 million in 1990 to $7.2 million (seegraph). Sales of the UM 9 had grown to 68% of all ATL sales bythe fourth quarter of 1991.

"With ATL's commitment of its resources to high performance,premium-priced systems, its position in the low- to mid-pricedultrasound market has been allowed to decline," the statementsaid.

The firm's Ultramark 4 general-purpose, non-color-flow scannerwas once ATL's primary product, but accounted for only about 20%of total revenue last year. ATL discontinued another lower endsystem, the UM 5.

ATL's strategic shift matches the general makeup of the ultrasoundmarket. Worldwide, radiology ultrasound sales account for 41%of the total market relative to other applications. Premium scannerscosting over $150,000 account for 40% of the world ultrasoundmarket when divided on the basis of price, according to the proxystatement (see graphs).

The vendor's primary market is its home base, with U.S. salesaccounting for 70% of total revenue in 1991. The ultrasound marketoverall is split more evenly. U.S. sales account for slightlyless than half, with the rest of the market split mainly betweenEurope and Japan (see graphs).

ATL is not active in the Japanese ultrasound market, whichremains a hard nut for foreign firms to crack.

"Its complex distribution system is highly competitiveand Japanese manufacturers account for almost all sales,"according to the proxy statement.

Medical ultrasound is the fastest growing imaging modalityworldwide. The ultrasound segment reached about $1.8 million in1991 out of a total medical imaging market estimated at $8 billion,the company said.

Recent Videos
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.